New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
11:02 EDTJD, LULU, MONT, NSR, RH, ULTA, OREX, OPEN, FIO, ACHNOptions with decreasing implied volatility
Options with decreasing implied volatility: OREX MONT ACHN ULTA LULU FIO RH JD OPEN NSR
News For OREX;MONT;ACHN;ULTA;LULU;FIO;RH;JD;OPEN;NSR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
10:23 EDTJDJD.com initiated with a Buy at T.H. Capital
Subscribe for More Information
August 3, 2015
10:00 EDTULTAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:30 EDTULTAULTA Beauty initiated with a Hold at Deutsche Bank
Subscribe for More Information
05:41 EDTACHNAchillion announces Janssen initiated study to evaluate simeprevir and odalasvir
Achillion announced that Alios Biopharma part of the Janssen Pharmaceutical JNJ)) has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 in healthy volunteers. This phase I study is an open-label, two-group study of simeprevir and odalasvir, a HCV NS5A inhibitor, on the pharmacokinetics of AL-335, a nucleotide-based HCV polymerase inhibitor. The primary objective of the study is to investigate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 when administered in combination to healthy volunteers. As previously announced on May 19, 2015, Achillion has granted Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillionís HCV assets which include odalasvir, ACH-3422, and sovaprevir.
July 31, 2015
10:02 EDTRHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:43 EDTRHRestoration Hardware initiated with a Hold at Evercore ISI
Subscribe for More Information
July 30, 2015
16:30 EDTNSRNeuStar acquires Bombora for $86.9M, sees $8M contribution to 2015 revenue
Subscribe for More Information
16:28 EDTNSRNeuStar raises FY15 adjusted EPS to $4.34-$4.51, consensus $4.43
Subscribe for More Information
16:27 EDTNSRNeuStar reports Q2 adjusted EPS $1.10, consensus $1.07
Subscribe for More Information
July 27, 2015
10:01 EDTJDJD.com falls, levels to watch
Shares are down over 4.7% to $33 at time of writing following the large sell-off in Chinese markets overnight. At the current price support is at the session low at $32.11. Resistance is at $33.48.
July 23, 2015
11:54 EDTOREXOptions with increasing call volume
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use